CluenexCVS Health CVS
CVS Health scores weak on business quality (3.6 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What CVS Health does
CVS Health makes money by operating a massive pharmacy retail chain, pharmacy benefit manager, and Aetna health insurance provider, charging premiums, service fees, and retail sales to everyday consumers and employers. The company is currently reworking primary care around value-based models and rolling out 2027 Aetna Medicare plans to stabilize care access and member support.
- What it does best
CVS dominates physical health touchpoints through its massive retail and pharmacy footprint, driving heavy foot traffic. Its gross margin sits at 14.2%, trailing peers like DGX at 33.2% due to low-margin retail drug sales, but its sheer scale creates an unmatched local healthcare distribution network.
- The main risk
Medical cost pressures in the insurance segment threaten margins, evidenced by a thin operating margin of 2.1%. If utilization spikes above projections in Aetna plans, earnings take an immediate hit.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin rests at a thin 2.1% and FCF margin at 13%, with profitability under persistent pressure from high medical costs. Scale does not currently translate into wide margins.
Scale is the primary moat, locking in tens of millions of retail and insurance customers. Its gross margin ranks in the bottom decile of its sector at 6th percentile.
Revenue growth is running at 7.8%, up from past years as top-line demand expands across pharmacy and insurance segments, sitting right in the middle of its sector.
Net debt sits at $54.0 billion against $10.6 billion in cash, paired with a low interest coverage of 2.8x. Free cash flow reached $11.8B, but heavy debt leaves the balance sheet soft.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on CVS
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
CVS Health scores weak on the Cluenex quality check (3.6 of 10), measured against its own industry. Profitability is weak, moat weak, growth steady and financial health weak.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Nov 4, 2026, before the open.
See CVS today
- Today's verdict on CVS, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “CVS Health (CVS)”, https://cluenex.com/stocks/cvs/, data as of Oct 10, 2026.